Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism - The COSIMO study

Affiliations

• ¹ Department of Haematological Medicine, Guys and St Thomas' NHS Foundation Trust, King's College London, Westminster Bridge Road, London, United Kingdom. Electronic address: alexander.cohen@kcl.ac.uk.
• ² Joint Centre for Cancer Studies, Hull York Medical School, QCOH, Castle Hill Hospital, Hull, United Kingdom. Electronic address: anthony.maraveyas@hey.nhs.uk.
• ³ Thrombosis Research Unit, Department of Medicine I, Division Hematology, University Hospital "Carl Gustav Carus" Dresden, Dresden, Germany. Electronic address: jan.beyer@uniklinikum-dresden.de.
• ⁴ Division of Hematology, University of British Columbia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Electronic address: alee14@bccancer.bc.ca.
• ⁵ Bayer AG, Wuppertal, Germany. Electronic address: kerstin.folkerts@bayer.com.
• ⁶ Bayer AG, Wuppertal, Germany. Electronic address: khaled.abdelgawwad@bayer.com.
• ⁷ Bayer US LLC, Whippany, NJ, United States. Electronic address: yoriko.desanctis@bayer.com.
• ⁸ Bayer AG, Berlin, Germany. Electronic address: samuel.fatoba@bayer.com.
• ⁹ Bayer AG, Wuppertal, Germany. Electronic address: luke.bamber@bayer.com.
• ¹⁰ Bayer AG, Berlin, Germany. Electronic address: miriam.bach@bayer.com.
• ¹¹ CESP-Center for Public Health Research, University of Milan Bicocca, Monza, Italy; IRCCS Multimedica, Sesto San Giovanni, Italy. Electronic address: lorenzo.mantovani@unimib.it.